Literature DB >> 25196226

Biomarker evaluation in randomized trials: addressing different research questions.

Stuart G Baker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25196226      PMCID： PMC4160815          DOI： 10.1002/sim.6202

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


× No keyword cloud information.
  4 in total

1.  Potential impact of genetic testing on cancer prevention trials, using breast cancer as an example.

Authors:  S G Baker; L S Freedman
Journal:  J Natl Cancer Inst       Date:  1995-08-02       Impact factor: 13.506

Review 2.  Biomarkers, subgroup evaluation, and clinical trial design.

Authors:  Stuart G Baker; Barnett S Kramer; Daniel J Sargent; Marco Bonetti
Journal:  Discov Med       Date:  2012-03       Impact factor: 2.970

3.  Evaluating markers for selecting a patient's treatment.

Authors:  Xiao Song; Margaret Sullivan Pepe
Journal:  Biometrics       Date:  2004-12       Impact factor: 2.571

4.  Randomized reverse marker strategy design for prospective biomarker validation.

Authors:  Kevin H Eng
Journal:  Stat Med       Date:  2014-03-18       Impact factor: 2.373
  4 in total
  3 in total

1.  Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes.

Authors:  Stuart G Baker; Barnett S Kramer
Journal:  Clin Trials       Date:  2014-11-10       Impact factor: 2.486

Review 2.  Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Authors:  Miranta Antoniou; Ruwanthi Kolamunnage-Dona; Andrea L Jorgensen
Journal:  J Pers Med       Date:  2017-01-25

3.  Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement.

Authors:  Peter J Mazzone; Catherine Rufatto Sears; Doug A Arenberg; Mina Gaga; Michael K Gould; Pierre P Massion; Vish S Nair; Charles A Powell; Gerard A Silvestri; Anil Vachani; Renda Soylemez Wiener
Journal:  Am J Respir Crit Care Med       Date:  2017-10-01       Impact factor: 21.405
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.